The Application of Photosensitive Hydrogel in Intranasal Endoscopic Dacryocystorhinostomy

After endoscopic dacryocystonasal anastomosis, granulation and/or cicatricial adhesion are the main reasons for surgical failure. How to achieve the ideal fit between the lacrimal sac flap and the nasal mucoperiosteal flap and avoid the proliferation of granulation and cicatricial adhesion is very important for the success of the operation. In this study, "photocoupling reaction" technology was used to achieve seamless integration and strong adhesion of photosensitive hydrogel materials to the wound, and the photohydrogel was applied to suture free adhesion and wound repair of the lacrimal cyst mucosal flap and nasal mucosal flap in endoscopic nasal Dacryocystostomy (En-DCR), and its feasibility, safety and effectiveness were evaluated.

Inclusion criteria

• Voluntarily participate in this clinical study and sign the informed consent;
• Gender is not limited, age 18-75 years old;
• The patient had symptoms and signs of chronic dacryocystitis, and the results of lacrimal passage irrigation suggested that the lower rush and return or upper rush and lower return, accompanied by mucous or purulent discharge reflux;
• Lacrimal duct angiography suggests nasolacrimal duct obstruction without lacrimal canaliculi and/or duct obstruction.

Exclusion criteria

• Age < 18 or > 75 years old;
• Previous history of dacryocystonasal anastomosis;
• Abnormal coagulation function;
• Tumors of lacrimal passage, especially in patients with papilloma or malignant tumors;
• in the acute dacryocystitis attack stage;
• obvious scar constitution;
• Complicated with serious nasal diseases, such as severe allergic rhinitis, chronic rhinosinusitis and nasal polyps, acute suppurative rhinosinusitis, severe atrophic rhinitis, and severe deviation of nasal septum;
• Have serious heart, liver, kidney, lung and other basic diseases, can not tolerate general anesthesia;
• Distance from the hospital, postoperative review is not convenient;
• Participated in other clinical trials within the last 3 months;
• Any medical history that the investigator determines may interfere with the test results or increase the patient's risk.